Previous 10 | Next 10 |
Voyager Therapeutics press release ( NASDAQ: VYGR ): Q2 GAAP EPS of -$0.50 misses by $0.02 . The company had collaboration revenue of $0.7 million for the second quarter of 2022, compared to $1.4 million for the same period in 2021. Cash, cash equivalents and marke...
Pipeline prioritizes tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's disease and SOD1 ALS, each program employing efficient paths to human proof of biology Targeting development candidate selection for priority programs in 2022 and H1 2023 Cr...
Novel passive antibodies bind to paired helical filamentous tau and inhibit propagation of pathological tau Vectorized antibody demonstrates durable CNS expression more than six months post-dose Research presented at the Alzheimer’s Association International Confe...
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, will report second quarter 2022 financial and operating result...
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced the appointment of Catherine J. Mackey, Ph.D. to its Board of D...
Neurocrine has chosen to terminate development of NBIb-1817, the gene therapy for Parkinson's it acquired through its partnership with Voyager. Ingrezza sales have been knocked off stride by COVID-19, and it remains to be seen how quickly the company can regain the sort of growth that...
Voyager Therapeutics (VYGR) has lost ~12.8% today after BTIG downgraded the stock to neutral from buy, noting the multiple clinical holds faced by the company. The price target of $6.50 per share implies a ~18.8% downside to the previous close.Even though the analyst Thomas Shrader ...
Moleculin Biotech (MBRX) -21% on launch of public offering.NTN Buzztime (NTN) -16%.PEDEVCO (PED) -13% after pricing stock offering.Ocugen (OCGN) -14%.Voyager Therapeutics (VYGR) -13% on termination of Parkinson’s collaboration with Neurocrine Bio.Titan Med...
Gainers: [[ISBC]] +13.2%. [[RDUS]] +8.6%. [[SRGA]] +8.5%. [[ARAY]] +8.3%. [[GOOG]] +7.8%.Losers: [[TENB]] -10.6%. [[VYGR]] -6.3%. [[TLSA]] -5.3%. [[EVLO]] -4.6%. [[RAIL]] -4.5%. For further details see: ARAY, GOOG, TENB and RDUS among after-hours movers
Voyager Therapeutics (VYGR) said that its partner Neurocrine Biosciences (NBIX) had given it a notice of termination of the Parkinson’s disease portion of their collaboration agreement, effective August 2, 2021.Voyager is evaluating the complete financial impact of the termi...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...